How does mebendazole synergize with docetaxel for prostate cancer?
In preclinical animal models, researchers co-encapsulated docetaxel and mebendazole into liposomes to deliver the combination directly to tumors, successfully suppressing prostate tumor growth.
Mebendazole synergizes with docetaxel in the treatment of prostate cancer through the dual targeting of distinct aspects of microtubule dynamics. Mebendazole was specifically identified as a lead candidate during a drug-repurposing screen aimed at finding compounds capable of overcoming chemoresistance and enhancing docetaxel’s modest survival impact in prostate cancer patients.
When the two drugs are used in combination, they produce several profound anti-tumor effects:
Enhanced Mitotic Arrest and Apoptosis: Because both drugs attack the microtubule structure in different ways, their combination significantly increases the G2/M mitotic block and subsequent apoptotic cell death.
Multipolar Spindle Formation: The combined treatment completely disrupts proper cell division. Strikingly, no cells divide correctly; instead, they form abnormal multipolar spindles.
Aneuploidy: Aberrant cell division driven by multipolar spindles results in aneuploid daughter cells (cells with an abnormal number of chromosomes), which further drive cancer cell death.
In preclinical animal models, researchers co-encapsulated docetaxel and mebendazole into liposomes to deliver the combination directly to tumors. This combined liposomal therapy successfully suppressed prostate tumor growth and extended progression-free survival in vivo, providing a strong rationale for further clinical evaluation of the mebendazole-docetaxel combination.